| Literature DB >> 28152004 |
Bing-Yun Li1, Yan-Mei Yang1, Yang Liu1, Jing Sun1, Yan Ye1, Xiao-Na Liu1, Hong-Xu Liu1, Zhen-Qi Sun1, Mang Li1, Jing Cui1, Dian-Jun Sun1, Yan-Hui Gao1.
Abstract
OBJECTIVE: Prolactin (PRL) has been reported to be associated with increased bone turnover, and increased bone turnover is also a feature of skeletal fluorosis (SF). Autocrine/paracrine production of PRL is regulated by the extrapituitary promoter and a polymorphism in the extrapituitary PRL promoter at -1149 (rs1341239) is associated with disturbances of bone metabolism in other diseases. Here, we have investigated the possibility that the rs1341239 polymorphism is associated with SF, which results from the consumption of brick tea.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28152004 PMCID: PMC5289533 DOI: 10.1371/journal.pone.0171011
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Representative images of brick-tea type skeletal fluorosis by X-ray examination.
Normal (a) and (b): Normal forearm and shin. Mild (c) and (d): The interosseous membrane in the forearm or lower leg bone was mildly ossified with rough edges (arrows). Moderate (e) and (f): The radial crest and the border were enlarged; the interosseous membrane in the forearm or shin was ossified with serration or wave edge (arrows). Severe (g) and (h): The radial crest was enlarged and the border was obviously enlarged so that ulna and elbow joints presented severe degenerative changes; the interosseous membrane in the forearm or shin was obviously ossified with large shape (arrows).
General characteristics of study populations.
| Characteristics | Cases | Controls | SF p* | Ethnicity p# | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Total n (%) | Tibetan n (%) | Kazakh n (%) | Mongolian n (%) | Total n (%) | Tibetan n (%) | Kazakh n (%) | Mongolian n (%) | |||
| 279 | 123 (44.1) | 98 (35.1) | 58 (20.8) | 580 | 185 (31.9) | 192 (33.1) | 203 (35.0) | |||
| Sex | 0.01 | 0.438 | ||||||||
| Male | 130 (46.6) | 64 (52.0) | 44 (44.9) | 22 (37.9) | 217 (37.4) | 71 (38.4) | 65 (33.9) | 81 (39.9) | ||
| Female | 149 (53.4) | 59 (48.0) | 54 (55.1) | 36 (62.1) | 363 (62.6) | 114 (61.6) | 127 (66.1) | 122 (60.1) | ||
| Age | <0.001 | 0.030 | ||||||||
| ~45 | 54 (19.4) | 20 (16.3) | 20 (20.4) | 14 (24.1) | 235 (40.5) | 78 (42.2) | 66 (34.4) | 91 (44.8) | ||
| 45~65 | 167 (59.9) | 66 (53.7) | 63 (64.3) | 38 (65.5) | 282 (48.6) | 87 (47.0) | 96 (50.0) | 99 (48.8) | ||
| 65~ | 58 (20.8) | 37 (30.1) | 15 (15.3) | 6 (10.3) | 63 (10.9) | 20 (10.8) | 30 (15.6) | 13 (6.4) | ||
| IF | 0.007 | <0.001 | ||||||||
| ~3.5 mg/d | 78 (28.0) | 27 (22.0) | 23 (23.5) | 28 (48.3) | 168 (29.0) | 41 (22.2) | 45 (23.4) | 82 (40.4) | ||
| 3.5~7.0 mg/d | 88 (31.5) | 33 (26.8) | 37 (37.8) | 18 (31.0) | 236 (40.7) | 78 (42.2) | 57 (29.7) | 101 (49.8) | ||
| 7.0 mg/d | 113 (40.5) | 63 (51.2) | 38 (38.8) | 12 (20.7) | 176 (30.3) | 66 (35.7) | 90 (46.9) | 20 (9.9) | ||
| UF | <0.001 | <0.001 | ||||||||
| ~1.6 mg/L | 64 (22.9) | 21 (17.1) | 18 (18.4) | 25 (43.1) | 206 (35.5) | 59 (31.9) | 24 (12.5) | 123 (60.6) | ||
| 1.6~3.2 mg/L | 109 (39.1) | 59 (48.0) | 32 (32.7) | 18 (31.0) | 204 (35.2) | 69 (37.3) | 72 (37.5) | 63 (31.0) | ||
| 3.2 mg/L | 106 (38.0) | 43 (35.0) | 48 (49.0) | 15 (25.9) | 170 (29.3) | 57 (30.8) | 96 (50.0) | 17 (8.4) | ||
| Grade of SF | <0.001 | |||||||||
| mild | 197 (70.6) | 68 (55.3) | 82 (83.7) | 47 (81.0) | ||||||
| moderate | 53 (19.0) | 32 (26.0) | 11 (11.2) | 10 (17.2) | ||||||
| severe | 29 (10.4) | 23 (18.7) | 5 (5.10) | 1 (1.7) | ||||||
p*, p value difference by fluorosis status; p#, p value difference by ethnicity (in case).
Occurrence of genotype and allele frequencies of the PRL rs1341239 polymorphism in three ethnical subjects.
| Ethnicity | n | Genotype | HWE p | MAF % | p* | |
|---|---|---|---|---|---|---|
| GG | GT+TT | |||||
| Tibetan | 308 | 280 | 28 | 0.403 | 4.55 | 0.001 |
| Kazakh | 290 | 185 | 105 | 0.942 | 20.17 | |
| Mongolian | 261 | 216 | 45 | 0.127 | 8.62 | |
N, number of subjects; HWE, Hardy-Weinberg equilibrium test; MAF, minor allele frequency; p*, significant difference by ethnicity.
Associations between skeletal fluorosis and the PRL rs1341239 genotype (overall or stratified by ethnicity).
| Genotype | Case (n) | Control (n) | crude OR (95% CI) | adjusted OR (95% CI) | |
|---|---|---|---|---|---|
| All subjects | |||||
| GG | 227 | 454 | 1 (ref) | 1 (ref) | |
| GT+TT | 52 | 126 | 1.212 (0.845–1.737) | 1.167 (0.799–1.705) | |
| Tibetan | |||||
| GG | 112 | 168 | 1 (ref) | 1 (ref) | |
| GT+TT | 11 | 17 | 0.971 (0.438–2.150) | 1.198 (0.492–2.917) | |
| Kazakh | |||||
| GG | 70 | 115 | 1 (ref) | 1 (ref) | |
| GT+TT | 28 | 77 | 0.597 (0.353–1.010) | ||
| Mongolian | |||||
| GG | 45 | 171 | 1 (ref) | 1 (ref) | |
| GT+TT | 13 | 32 | 1.544 (0.749–3.182) | 1.506 (0.695–3.262) |
a, Adjusted for age, gender, ethnicity, fluoride intake and urine fluoride.
b, p = 0.051.
Associations between skeletal fluorosis and the PRL rs1341239 genotype in different age groups (overall or stratified by ethnicity).
| Genotype | <45 | 45–60 | >60 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Case (n) | Control (n) | adjusted OR (95% CI) | Case (n) | Control (n) | adjusted OR (95% CI) | Case (n) | Control (n) | adjusted OR (95% CI) | ||
| All subjects | ||||||||||
| GG | 50 | 187 | 1 (ref) | 132 | 222 | 1 (ref) | 45 | 45 | 1 (ref) | |
| GT+TT | 4 | 48 | 35 | 60 | 1.180 (0.722–1.928) | 13 | 18 | 0.974 (0.388–2.448) | ||
| Tibetan | ||||||||||
| GG | 20 | 66 | 60 | 82 | 1 (ref) | 32 | 20 | |||
| GT+TT | 0 | 12 | —— | 6 | 5 | 1.87 (0.515–6.793) | 5 | 0 | —— | |
| Kazakh | ||||||||||
| GG | 18 | 40 | 1 (ref) | 43 | 63 | 1 (ref) | 9 | 12 | 1 (ref) | |
| GT+TT | 2 | 26 | 20 | 33 | 0.944 (0.473–1.885) | 6 | 18 | 0.328 (0.065–1.646) | ||
| Mongolian | ||||||||||
| GG | 12 | 81 | 1 (ref) | 29 | 77 | 1 (ref) | 4 | 13 | 1 (ref) | |
| GT+TT | 2 | 10 | 1.054 (0.177–6.286) | 9 | 22 | 1.185 (0.445–3.155) | 2 | 0 | 1.147 (0.105–12.515) | |
Adjusted for gender, ethnicity, fluoride intake and urine fluoride.
a, p = 0.021
b, p = 0.013.
Associations between skeletal fluorosis and the PRL rs1341239 genotype in different gender groups (overall or stratified by ethnicity).
| Genotype | Females | Males | |||||
|---|---|---|---|---|---|---|---|
| Case (n) | Control (n) | adjusted OR | Case (n) | Control (n) | adjusted OR | ||
| All subjects | |||||||
| GG | 118 | 273 | 1(ref) | 109 | 181 | 1(ref) | |
| GT+TT | 31 | 90 | 0.770 (0.474–1250) | 21 | 36 | 0.954 (0.511–1.780) | |
| Tibetan | |||||||
| GG | 54 | 104 | 1(ref) | 58 | 64 | 1(ref) | |
| GT+TT | 5 | 10 | 1.664 (0.467–5.931) | 6 | 7 | 1.009 (0.284–3.593) | |
| Kazakh | |||||||
| GG | 39 | 69 | 1(ref) | 31 | 46 | 1(ref) | |
| GT+TT | 15 | 58 | 13 | 19 | 0.979 (0.4–2.396) | ||
| Mongolian | |||||||
| GG | 25 | 100 | 1(ref) | 20 | 71 | 1(ref) | |
| GT+TT | 11 | 22 | 1.827 (0.710–4.703) | 2 | 10 | 0.661 (0.128–3.425) | |
Adjusted for age, ethnicity, fluoride intake and urine fluoride.
a, p = 0.016.
Associations between skeletal fluorosis and the PRL rs1341239 genotype in different IF groups (overall or stratified by ethnicity).
| Genotype | <3.5 mg/d | 3.5–7.0 mg/d | >7 mg/d | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Case (n) | Control (n) | adjusted OR (95% CI) | Case (n) | Control (n) | adjusted OR (95% CI) | Case (n) | Control (n) | adjusted OR (95% CI) | ||
| All subjects | ||||||||||
| GG | 64 | 135 | 1 (ref) | 70 | 181 | 1 (ref) | 93 | 138 | 1 (ref) | |
| GT+TT | 14 | 33 | 0.916 (0.504–1.662) | 18 | 55 | 1.016 (0.624–1.655) | 20 | 38 | 0.882 (0.475–1.636) | |
| Tibetan | ||||||||||
| GG | 22 | 41 | 31 | 68 | 1 (ref) | 59 | 59 | 1 (ref) | ||
| GT+TT | 5 | 0 | —— | 2 | 10 | 0.717 (0.129–3.998) | 4 | 7 | 0.53 (0.127–2.218) | |
| Kazakh | ||||||||||
| GG | 20 | 21 | 1 (ref) | 25 | 31 | 1 (ref) | 25 | 63 | 1 (ref) | |
| GT+TT | 3 | 24 | 12 | 26 | 0.459 (0.178–1.187) | 13 | 27 | 1.686 (0.690–4.116) | ||
| Mongolian | ||||||||||
| GG | 22 | 73 | 1 (ref) | 14 | 82 | 1 (ref) | 9 | 16 | 1 (ref) | |
| GT+TT | 6 | 9 | 2.3 (0.717–7.381) | 4 | 19 | 0.944 (0.255–3.495) | 3 | 4 | 1.11 (0.107–11.565) | |
Adjusted for age, gender, ethnicity and urine fluoride.
a, p = 0.003.
Associations between skeletal fluorosis and the PRL rs1341239 genotype in different UF groups (overall or stratified by ethnicity).
| Genotype | <1.6 mg/L | 1.6–3.2 mg/L | >3.2 mg/L | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Case (n) | Control (n) | adjusted OR | Case (n) | Control (n) | adjusted OR | Case (n) | Control (n) | adjusted OR | ||
| All subjects | ||||||||||
| GG | 50 | 166 | 1 (ref) | 96 | 158 | 81 | 130 | |||
| GT+TT | 14 | 40 | 1.154 (0.558–2.386) | 13 | 46 | 25 | 40 | 1.107 (0.598–2.047) | ||
| Tibetan | ||||||||||
| GG | 16 | 54 | 1 (ref) | 57 | 61 | 1 (ref) | 39 | 53 | ||
| GT+TT | 5 | 5 | 4.053 (0.893–18.398) | 2 | 8 | 0.266 (0.047–1.525) | 4 | 4 | 1.976 (0.360–10.848) | |
| Kazakh | ||||||||||
| GG | 13 | 12 | 1 (ref) | 26 | 40 | 1 (ref) | 31 | 63 | ||
| GT+TT | 5 | 12 | 0.299 (0.067–1.323) | 6 | 32 | 17 | 33 | 1.100 (0.509–2.377) | ||
| Mongolian | ||||||||||
| GG | 21 | 100 | 1 (ref) | 13 | 57 | 1 (ref) | 11 | 14 | ||
| GT+TT | 4 | 23 | 0.866 (0.255–2.942) | 5 | 6 | 3.960 (0.961–16.315) | 4 | 3 | 1.181 (0.170–8.194) | |
Adjusted for age, gender, ethnicity and fluoride intake.
a, p = 0.035
b, p = 0.037.